

Jubilant Life Sciences (BVI) Limited
Balance Sheet as at 31 March 2021

		USD	INR (In Thousands)	USD	INR (In Thousands)
	Notes	As at 31 March 2021		As at 31 March 2020	
ASSETS					
Non-current assets					
Financial assets					
Investments	1	2,547,001	186,211	2,547,001	192,719
Total non-current assets		2,547,001	186,211	2,547,001	192,719
Current assets					
Financial assets					
Cash and cash equivalents	2	6,094	446	86,920	6,577
Other current assets	3	-	-	2,375	179
Total current assets		6,094	446	89,295	6,756
Total assets		2,553,095	186,657	2,636,296	199,475
EQUITY AND LIABILITIES					
Equity					
Equity share capital	4	4,057,501	203,047	4,057,501	203,047
Other equity		(1,504,406)	(16,390)	(1,483,626)	(8,295)
Total equity		2,553,095	186,657	2,573,875	194,752
LIABILITIES					
Current liabilities					
Financial liabilities					
Trade payables	5	-	-	62,421	4,723
Total current liabilities		-	-	62,421	4,723
Total liabilities		-	-	62,421	4,723
Total equity and liabilities		2,553,095	186,657	2,636,296	199,475

Benny Thomas
Associate Vice President
Place: Bangaluru
Date: 3 June 2021

Jubilant Life Sciences (BVI) Limited
Statement of Profit and Loss for the year ended 31 March 2021

Particulars	Notes	USD	INR (In Thousands)	USD	INR (In Thousands)
		For the year ended 31 March 2021		For the year ended 31 March 2020	
Expenses					
Other expenses	6	20,780	1,522	19,197	1,359
Total expenses		20,780	1,522	19,197	1,359
Loss before tax		(20,780)	(1,522)	(19,197)	(1,359)
Tax expense					
- Current tax		-	-	-	-
Total tax expense		-	-	-	-
Loss after tax		(20,780)	(1,522)	(19,197)	(1,359)
Other comprehensive income					
<i>Items that will not be reclassified to profit or loss</i>					
Exchange differences on translation of foreign operations		-	(6,573)	-	18,544
Other comprehensive income for the year, net of tax		-	(6,573)	-	18,544
Total comprehensive (loss)/ income for the year		(20,780)	(8,095)	(19,197)	17,185

Benny Thomas
Associate Vice President
Place: Bangaluru
Date: 3 June 2021

Jubilant Life Sciences (BVI) Limited
Statement of changes in equity for the year ended 31 March 2021

			INR (In Thousands)
a) Equity share capital	Note	No. of shares	Amount
Balance as at 1 April 2019	4	4,057,501	203,047
Changes in equity share capital during the year			-
Balance as at 31 March 2020	4	4,057,501	203,047
Changes in equity share capital during the year			-
Balance as at 31 March 2021	4	4,057,501	203,047

b) Other Equity

	Reserves and surplus						
	Retained earnings		Exchange differences on translation of foreign operations	Capital Reserve		Total	
	USD	INR (In Thousands)	INR (In Thousands)	USD	INR (In Thousands)	USD	INR (In Thousands)
Balance as at 1 April 2019	(51,163)	46,205	27,826	-	-	(51,163)	74,031
Loss for the year	(19,197)	(1,359)	-	-	-	(19,197)	(1,359)
Recognised on account of amalgamation	(41,765)	(2,443)	-	(1,371,501)	(97,068)	(1,413,266)	(99,511)
Exchange loss during the year on translation of foreign operations	-	-	18,544	-	-	-	18,544
Balance as at 31 March 2020	(112,125)	42,403	46,370	(1,371,501)	(97,068)	(1,483,626)	(8,295)
Loss for the year	(20,780)	(1,522)	-	-	-	(20,780)	(1,522)
Exchange gain during the year on translation of foreign operations	-	-	(6,573)	-	-	-	(6,573)
Balance as at 31 March 2021	(132,905)	40,881	39,797	(1,371,501)	(97,068)	(1,504,406)	(16,390)

Benny Thomas
Associate Vice President
Place: Bangaluru
Date: 3 June 2021

Jubilant Life Sciences (BVI) Limited
Statement of Cash Flows for the year ended 31 March 2021

Particulars	USD	INR (In Thousands)	USD	INR (In Thousands)
	For the year ended 31 March 2021		For the year ended 31 March 2020	
A. Cash flow from operating activities				
Loss before tax	(20,780)	(1,522)	(19,197)	(1,359)
Operating cash flow before working capital changes				
Decrease in other current assets	2,375	179	1,120	79
(Decrease)/ Increase in trade payables	(62,421)	(4,723)	18,077	1,280
Cash generated from operations	(80,826)	(6,066)	0	0
Income tax paid (net of refund)	-	-	-	-
Net cash used in operating activities	(80,826)	(6,066)	-	-
B. Effect of exchange rate changes		(65)		565
Net decrease in cash and cash equivalents	(80,826)	(6,131)	-	566
Add: cash and cash equivalents at the beginning of year*	86,920	6,577	86,920	6,011
Cash and cash equivalents at the end of the year (Refer note No:2)	6,094	446	86,920	6,577

* Opening Cash and cash equivalent of Jubilant Biosys (BVI) Ltd. added due to Amalgamation.

Benny Thomas
Associate Vice President
Place: Bangaluru
Date: 3 June 2021

Jubilant Life Sciences (BVI) Limited
Notes to the financial statements for the year ended 31 March 2021

	USD	INR (In Thousands)	USD	INR (In Thousands)
	As at 31 March 2021		As at 31 March 2020	
Note 1. Non-current investments				
Jubilant Drug Development Pte Ltd	2,547,001	186,211	2,547,001	192,719
2,547,001 (31 March 2020 : 2,547,001 equity share with no par value)				
	2,547,001	186,211	2,547,001	192,719
Note 2. Cash and cash equivalent				
Balances with banks:				
- On current accounts	6,094	446	86,920	6,577
	6,094	446	86,920	6,577
Note 3. Other current assets				
Prepaid expenses	-	-	2,375	179
	-	-	2,375	179

Jubilant Life Sciences (BVI) Limited
Notes to the financial statements for the year ended 31 March 2021

Note 4: Equity share capital

	USD	INR (In Thousands)	USD	INR (In Thousands)
	As at 31 March 2021		As at 31 March 2020	
Issued, subscribed and paid up share capital				
4,057,501 (31 March 2020: 4,057,501 Equity shares of USD 1 each)	4,057,501	203,047	4,057,501	203,047
	4,057,501	203,047	4,057,501	203,047

1). Movement in equity share capital

	Note	No. of shares	USD	INR (' In Thousands)
Balance as at 1 April 2019	4	4,057,501	4,057,501	203,047
Changes in equity share capital during the year				-
Balance as at 31 March 2020	4	4,057,501	4,057,501	203,047
Changes in equity share capital during the period				-
Balance as at 31 March 2021	4	4,057,501	4,057,501	203,047

2) The Company has only one class of shares referred to as equity shares having par value of USD 1 each. Each holder of equity shares is entitled to one vote per share.

3) In the event of liquidation of the Company, the holders of equity shares will be entitled to receive any of the remaining assets of the Company after distribution of all preferential amounts, if any, in proportion to their shareholding. However no such preferential amounts exist currently.

4) The details of shareholders holding more than 5% shares in the company : -

Name of the Shareholder	As at 31 March 2021		As at 31 March 2020	
	No of shares	% holding in the class	No of shares	% holding in the class
Drug Discovery and Development Solutions Ltd.	4,057,501	100%	4,057,501	100%

Jubilant Life Sciences (BVI) Limited
Notes to the financial statements for the year ended 31 March 2021

	USD	INR (In Thousands)	USD	INR (In Thousands)
	As at 31 March 2021		As at 31 March 2020	
Note 5. Trade payables				
Trade payables-others	-	-	62,421	4,723
	-	-	62,421	4,723

	USD	INR (In Thousands)	USD	INR (In Thousands)
	For the year ended 31 March 2021		For the year ended 31 March 2020	
Note 6. Other expenses				
Legal, professional and consultancy charges	20,424	1,496	18,747	1,327
Bank charges	356	26	450	32
	20,780	1,522	19,197	1,359